Adherencia al tratamiento con adalimumab, golimumab y ustekinumab en pacientes con enfermedad inflamatoria intestinal
Sign Up to like & getrecommendations! Published in 2020 at "Farmacia Hospitalaria"
DOI: 10.7399/fh.11325
Abstract: Objective: Inflammatory bowel disease comprises a group of chronic relapsing inflammatory disorders affecting the bowel. In the last decade, the advent of biological drugs brought about a drastic change in the treatment of the disease. Adalimumab, golimumab and… read more here.
Keywords: adherence; adherencia tratamiento; golimumab ustekinumab; adalimumab golimumab ... See more keywords